NCT05227664 - A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 23, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

December 30, 2026

Conditions

Metastatic Triple-negative Breast CancerLocally Advanced Triple-negative Breast Cancer

Interventions

DRUG

AK117

Intravenous (IV) infusion

DRUG

AK112

Intravenous (IV) infusion

DRUG

Nab paclitaxel

Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

DRUG

paclitaxel

Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Trial Locations (2)

Unknown

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Xiangyang Central Hospital, Xiangyang